Update: Sanofi Will Hire A New CEO Shortly, But Growth Remains Muted
Early Retiree - at Seeking Alpha - Thu Feb 05, 3:30AM CST
SNY: 50.52 (-0.27)
MannKind earns milestone
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 7:08AM CST
SNY: 50.52 (-0.27), MNKD: 3.99 (+0.36)
FDA clears Sanofi's four-strain flu vaccine
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:26AM CST
SNY: 50.52 (-0.27)
Disgruntled ex-employee says Sanofi paid kickbacks to boost drug sales
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 7:12AM CST
SNY: 50.52 (-0.27)
FDA approves expanded label for Sanofi TB med
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 8:32AM CST
SNY: 50.52 (-0.27)
Sanofi backs out of commercialization deal with Pozen
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 6:41AM CST
POZN: 6.71 (-0.01), SNY: 50.52 (-0.27)
Europe Ad Comm recommends approval of Celgene's Otezla
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:04AM CST
SHPG: 254.45 (+3.99), PFE: 33.99 (+0.05), PLX: 2.13 (+0.03), SNY: 50.52 (-0.27), CELG: 115.53 (+0.45)
Europe Ad Comm supports approval of Genzyme Gaucher drug
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 6:38AM CST
SHPG: 254.45 (+3.99), PFE: 33.99 (+0.05), PLX: 2.13 (+0.03), SNY: 50.52 (-0.27)
Dupilumab tagged a Breakthrough Therapy for atopic dermatitis
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 7:16AM CST
SNY: 50.52 (-0.27), REGN: 489.01 (-2.42)
Positive clinical trial results for alirocumab presented at AHA meeting
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 11:35AM CST
AMGN: 162.36 (+0.38), SNY: 50.52 (-0.27), REGN: 489.01 (-2.42)
Genzyme and Isis Pharma announce presentation on cardiac benefits of Kynamro
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:37PM CST
ISIS: 62.55 (+0.10), SNY: 50.52 (-0.27)
Eylea expands label in Japan
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 8:32AM CST
SNY: 50.52 (-0.27), REGN: 489.01 (-2.42)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), AMGN: 162.36 (+0.38), TEVA: 60.23 (-0.99), THRX: 16.25 (+0.18), GSK: 44.77 (-0.22), SNY: 50.52 (-0.27), REGN: 489.01 (-2.42), NVS: 103.75 (-0.15)
Update: Sanofi Destroys Shareholder Value
Early Retiree - Seeking Alpha - Thu Oct 30, 8:56AM CDT
After downplaying the rumors yesterday, this morning the BOD of Sanofi removed the CEO . This is bad news for shareholders, and will certainly mark the start of a not very cooperative transition period. The background for the decision could easily...
SNY: 50.52 (-0.27)
Update: Sanofi Will Deliver Growth, But Later Than Expected
Early Retiree - at Seeking Alpha - Wed Oct 29, 9:46AM CDT
SNY: 50.52 (-0.27)
Sanofi Q3 net income up 8%
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:14AM CDT
SNY: 50.52 (-0.27)
Sanofi off premarket on soft diabetes forecast
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:31AM CDT
NVO: 56.75 (+0.06), SNY: 50.52 (-0.27)
BI begins enrollment in Phase 3 CRC trial
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 8:08AM CDT
MGNX: 30.84 (+0.42), IMMU: 4.12 (+0.05), ONCY: 0.71 (unch), ARQL: 1.87 (+0.06), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19), GILD: 109.30 (+0.56), SNY: 50.52 (-0.27), REGN: 489.01 (-2.42)
Dupilumab dermatitis trial underway
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:56AM CDT
PRGO: 194.50 (+0.35), VRX: 224.63 (+1.81), ANAC: 62.37 (-1.71), GSK: 44.77 (-0.22), SNY: 50.52 (-0.27), REGN: 489.01 (-2.42)
Amgen sues Sanofi and Regeneron
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 8:30AM CDT
AMGN: 162.36 (+0.38), SNY: 50.52 (-0.27), REGN: 489.01 (-2.42)